Table 2.
Clinical characteristics and outcomes of patients with CCNE1-amplified tumors in the “Discovery-TNBC” cohort
| Patient ID | Age | Stage | (Neo)Adjuvant chemotherapy | Response to neoadjuvant chemotherapy | Adjuvant radiation | RFS (months) | OS (months) |
|---|---|---|---|---|---|---|---|
| 1 | 50 | I | Declined | N/A | No | 58 | N/A |
| 2 | 50 | III | TAC | ypT2N0Mx | No | 11 | 23 |
| 3 | 46 | III | AC Carbo/nab-paclitaxel | ypT3N1Mx | Yes | 24 | 55 |
| 4 | 36 | III | AC-T | ypT0N1Mx | Yes | 13 | 18 |
| 5 | 35 | III | Carbo/taxol | ypT3N2aMx | Yes | 3 | 21 |
| 6 | 46 | III | Carbo/taxol | ypT3N3aMx | Yes | 13 | 43 |
| 7 | 50 | II | Docetaxel, cisplatin | ypT1N1Mx | Yes | 8 | 15 |
| 8 | 46 | III | Carbo/taxol, AC | ypT2N2aMx | Yes | 11 | 20 |
| 9 | 36 | II | Carbo/nab-paclitaxel | ypT1cN0Mx | Yes | 8 | 24 |
| 10 | 55 | III | AC-T (adjuvant) | pT4N2aMx | No | 46 | 60 |
| 11 | 46 | II | Carbo/taxol (adjuvant) | pT2N1Mx | No | 21 | 34 |
| 12 | 53 | III | AC-T | ypT1N1aMx | No | 9 | 16 |
| 13 | 48 | II | TC | ypT1cN1Mx | Yes | 3 | 38 |
AC adriamycin/cyclophosphamide, AC-T adriamycin/cyclophosphamide followed by paclitaxel, Carbo/taxol carboplatin/paclitaxel, TAC docetaxel/adriamycin/cyclophosphamide, TC docetaxel /cyclophosphamide, RFS relapse-free survival (surgery to first relapse), OS overall survival (surgery to death)